Australian TGA Approves Illuccix for Prostate Cancer Imaging
Filed with ASX · · 2 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call® Melbourne (Australia) – 02 November 2021. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has ® approved Illuccix (TLX591-CDx), the Company’s lead prostate cancer imaging product. 68 Illuccix (Kit for the preparation of Ga PSMA-11 Injection) is a positron emission tomography (PET) agent for the diagnostic ima
Telix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Activities Report and App 4C - September 2021 quarter
- IPAX-1 Presentation at Congress of Neurological Surgeons
- $12.1M R&D Tax Refund, Overseas Finding Increased to $139M
- FDA Extends New Drug Application Review Period for Illuccix
- FDA Approves Phase II Kidney Cancer Therapy Study
Later from Telix Pharmaceuticals
- Investor Presentation - November 2021
- Illuccix Granted Use Authorisation in Brazil
- NUCLIBER - Distribution Agreement for Illuccix in Spain
- Illuccix EU Regulatory Submission Progress Update
- FDA Approves Telix Prostate Cancer Imaging Product Illuccix
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals